Press release

Siemens Healthineers rounds off successful fiscal year 2022 with very good fourth quarter

Siemens Healthineers AG today announces its results for the fiscal year 2022 fourth quarter that ended September 30, 2022.

Published on November 9, 2022
<p><strong>Fiscal Year 2022 – Strength and resilience in a challenging environment </strong></p><ul><li>First year of “New Ambition” strategy phase successfully completed&nbsp;</li><li>Comparable revenue growth of 5.9% over the very good prior year; record revenue of around €21.7 billion&nbsp;</li><li>Revenue increased notably across all segments on a comparable basis: Imaging by 5.8%, Varian by 6.5%, Advanced Therapies by 5.7%, and Diagnostics by 6.6% including around €1.5 billion from rapid COVID-19 antigen tests&nbsp;</li><li>Equipment book-to-bill ratio outstanding at 1.23&nbsp;</li><li>Adjusted EBIT rose to almost €3.7 billion – with a good adjusted EBIT margin of 16.8%&nbsp;</li><li>Adjusted basic earnings per share rose 13% to €2.29&nbsp;</li><li>Proposed dividend of €0.95 per share (corresponding to a payout ratio of around 52% of net income) </li></ul><p><strong>Q4 Fiscal Year 2022 – Very good final quarter with strong development in revenue and earnings</strong></p><ul><li>Strong comparable revenue growth of 6.8% over the very good prior-year period; for the first time, quarterly revenue reached €6.0 billion&nbsp;</li><li>Revenue increased notably across all four segments on a comparable basis: Imaging by 8.1%, Advanced Therapies by 6.2%, Varian by 5.2%, and Diagnostics by 5.8% including €232 million from rapid COVID-19 antigen tests&nbsp;</li><li>Continued excellent equipment order intake, equipment book-to-bill ratio of 1.21&nbsp;</li><li>Adjusted EBIT margin rose to 16.8%&nbsp;</li><li>Adjusted basic earnings per share rose 22% from the prior-year quarter to €0.65 </li></ul><p><strong>Outlook for Fiscal Year 2023 </strong></p><p>For fiscal year 2023, we expect comparable revenue growth of between -1% and 1% compared with fiscal year 2022. Excluding revenue from rapid COVID-19 antigen tests, this corresponds to comparable revenue growth of between 6% and 8%. We expect adjusted basic earnings per share to be between €2.00 and €2.20.&nbsp;</p><p><strong>Bernd Montag, CEO of Siemens Healthineers AG: </strong></p><p><em>“Overall, the Siemens Healthineers team achieved excellent results in the fourth quarter and successfully concluded another fiscal year despite very difficult conditions. It is a sign of strength that in the first year of the ‘New Ambition’ phase of our Strategy 2025, we twice raised and achieved our annual targets for revenue growth and earnings. A continuous increase in order intake strengthens our confidence for the 2023 fiscal year.”</em></p>

Siemens Healthineers 2023

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at